KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the 2015 JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 3:30 p.m. EDT in New York.
To access the live audio webcast of the presentation, please visit the “Investors” section of the Company's website at www.trevenainc.com. Following the conclusion of the presentation, the webcast will be archived for 30 days.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (preclinical).